Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Bank of Japan Unveils New Inflation Gauge to Support Case for Future Rate Hikes 
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
Asian Currencies Weaken as Dollar Rebounds Amid Middle East Uncertainty and Japan Inflation Data 
Japan's Private Sector Growth Slows in March Amid Rising Costs and Middle East Uncertainty 
WTO Reform Talks Begin in Cameroon Amid Global Trade Tensions 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
9 Tips for Avoiding Tax Season Cyber Scams 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Trump Tariffs Show Minimal Economic Impact but Boost Federal Revenue, Study Finds 
Oil Prices Rebound as Iran Denies U.S. Talks Amid Gulf War Supply Fears 
Eli Lilly gets a subpoena from the U.S. Department of Justice with regards to its manufacturing factory in New Jersey that produces COVID-19 treatment called bamlanivimab. Based on the report, the DOJ wants the pharmaceutical company to forward some documents.
As per Reuters, while it was not specified what documents are being requested by the officials, they are something related to Eli Lilly’s factory site in Branchburg, New Jersey. The company said that it is actively participating and fully cooperating with the investigation.
The issue with Eli Lilly’s NJ plant
Earlier this month, some of Eli Lilly’s employees alleged that an executive in the NJ plant altered the documents so it can pass quality control without a problem. The papers are required by regulators for the operation of the company’s factory, but with the modification, the employees feared it would cause serious quality control issues.
It was relayed that in November 2019, inspectors from the U.S. Food and Drug Administration were sent over to check Eli Lilly’s Branchburg factory. They discovered that much of the data related to manufacturing processes were deleted while others were not inappropriately audited.
The pharmaceutical company is also said to be facing issues with its quality control and production at its plant in Indianapolis. This is the site where bamlanivimab and other medicines are being bottled.
Lilly conducting its own internal probe
As per Financial Post, Eli Lilly also launched its own investigation concerning the allegations. The company also hired counsel who will carry out an independent probe in its New Jersey facility.
“Lilly is deeply committed to manufacturing high-quality medicines for patients who need them, and the safety and quality of our products is our highest priority,” the firm stated.
In any case, while the investigation is ongoing, Eli Lilly published the subpoena issued to them by the DOJ. This move shows that the company is being transparent with the investigation and doing its best to resolve the problems too. Meanwhile, the company could not comment further on the case as of this time since a conclusion has not been reached yet.
